MXPA05008672A - Derivados de xantina sustituida con sulfonamida para el uso como inhibidores de fosfoenolpiruvato-carboxicinasa (pepck). - Google Patents

Derivados de xantina sustituida con sulfonamida para el uso como inhibidores de fosfoenolpiruvato-carboxicinasa (pepck).

Info

Publication number
MXPA05008672A
MXPA05008672A MXPA05008672A MXPA05008672A MXPA05008672A MX PA05008672 A MXPA05008672 A MX PA05008672A MX PA05008672 A MXPA05008672 A MX PA05008672A MX PA05008672 A MXPA05008672 A MX PA05008672A MX PA05008672 A MXPA05008672 A MX PA05008672A
Authority
MX
Mexico
Prior art keywords
xanthine derivatives
sulfonamide substituted
substituted xanthine
pepck inhibitors
pepck
Prior art date
Application number
MXPA05008672A
Other languages
English (en)
Inventor
Yun Weiya
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA05008672A publication Critical patent/MXPA05008672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a derivados de xantina sustituida con sulfonamida de la formula (I) o sales o profarmacos farmaceuticamente aceptable de los mismos, en donde R1, R2 y R3 son como se definen en la especificacion. Los compuestos de la formula (I) y las sales o profarmacos farmaceuticamente aceptables de los mismos muestran actividad como moduladores de la gluconeogenesis.
MXPA05008672A 2003-02-19 2004-02-12 Derivados de xantina sustituida con sulfonamida para el uso como inhibidores de fosfoenolpiruvato-carboxicinasa (pepck). MXPA05008672A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44856203P 2003-02-19 2003-02-19
PCT/EP2004/001289 WO2004074288A1 (en) 2003-02-19 2004-02-12 Sulfonamide substituted xanthine derivatives for use as pepck inhibitors

Publications (1)

Publication Number Publication Date
MXPA05008672A true MXPA05008672A (es) 2005-10-18

Family

ID=32908606

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008672A MXPA05008672A (es) 2003-02-19 2004-02-12 Derivados de xantina sustituida con sulfonamida para el uso como inhibidores de fosfoenolpiruvato-carboxicinasa (pepck).

Country Status (14)

Country Link
EP (1) EP1599477B1 (es)
JP (1) JP2006515337A (es)
KR (1) KR100728425B1 (es)
CN (1) CN100361992C (es)
AT (1) ATE385234T1 (es)
AU (1) AU2004213124A1 (es)
BR (1) BRPI0407695A (es)
CA (1) CA2514472A1 (es)
DE (1) DE602004011603T2 (es)
ES (1) ES2298722T3 (es)
MX (1) MXPA05008672A (es)
PL (1) PL378555A1 (es)
RU (1) RU2340613C2 (es)
WO (1) WO2004074288A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PL2448582T3 (pl) * 2009-06-29 2017-09-29 Agios Pharmaceuticals, Inc. Pochodne chinolino-8-sulfonamidowe mające działanie przeciwnowotworowe
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TWI549947B (zh) * 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
KR100657118B1 (ko) * 2002-06-12 2007-02-28 에프. 호프만-라 로슈 아게 포도당신합성 조절 활성을 갖는 아마이드 치환 크산틴 유도체

Also Published As

Publication number Publication date
RU2340613C2 (ru) 2008-12-10
CN100361992C (zh) 2008-01-16
AU2004213124A1 (en) 2004-09-02
ES2298722T3 (es) 2008-05-16
DE602004011603D1 (de) 2008-03-20
EP1599477A1 (en) 2005-11-30
PL378555A1 (pl) 2006-05-02
JP2006515337A (ja) 2006-05-25
DE602004011603T2 (de) 2009-01-29
EP1599477B1 (en) 2008-01-30
BRPI0407695A (pt) 2006-03-01
KR20050107432A (ko) 2005-11-11
CN1751044A (zh) 2006-03-22
RU2005128833A (ru) 2006-07-27
WO2004074288A1 (en) 2004-09-02
ATE385234T1 (de) 2008-02-15
KR100728425B1 (ko) 2007-06-13
CA2514472A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
MXPA05008672A (es) Derivados de xantina sustituida con sulfonamida para el uso como inhibidores de fosfoenolpiruvato-carboxicinasa (pepck).
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
MY147786A (en) Substituted morpholine and thiomorpholine derivatives
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
MXPA05008878A (es) Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
ATE377004T1 (de) Proteinkinaseinhibitoren
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
ATE457025T1 (de) Kinaseinhibitoren
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
ATE497949T1 (de) Tubulininhibitoren
IL163781A0 (en) Purine derivatives as kinase inhibitors
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
TW200504061A (en) Pyrazolopyridine derivatives
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
AU2005273867A1 (en) Benzothienopyridines for use as inhibitors of Eg5 kinesin
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
MXPA05009282A (es) Derivados de anilina sustituidos.
CA2487033A1 (en) Amide substituted xanthine derivatives with gluconeogenesis modulating activity

Legal Events

Date Code Title Description
FG Grant or registration